McMaster University spin-off company Fusion Pharmaceuticals and superconducting accelerator technology firm Niowave have inked a $5 million supply agreement for the development, production, and supply of actinium-225.
The cash will support Niowave's efforts to increase its production of actinium-225. As part of the deal, Fusion will have guaranteed access to a predetermined percentage of the radiopharmaceutical as well as preferred access to any excess supply.
Fusion is developing actinium-based targeted alpha therapy. Actinium-225 decay kills tumor cell DNA, it said. The company already has existing agreements with Canadian particle accelerator center TRIUMF and the U.S. Department of Energy.
